CRISPR Therapeutics AG, headquartered in Zug, develops gene-based medicines for serious diseases using its CRISPR/Cas9 platform and went public on October 19, 2016. The company focuses on gene editing to treat genetically-defined diseases and enhance cellular therapies.
Simeon George bought 989,812 shares of CRSP on 16 July at $52.03 per share, worth a total of $51.5M. They now own 1,730,179 CRSP shares, or a 134% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
